NS-229

Phase 2Small molecule

NS Pharma

NS-229 is one of 10 small molecule programs targeting Granulomatosis with Polyangiitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Granulomatosis With PolyangiitisRecruiting

Granulomatosis With PolyangiitisPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Granulomatosis With Polyangiitis

#DrugCompanyPhaseTrials

Rituxan

Roche

Approved

7 2

Rayos

RRoxane Laboratories

Approved

1 3

Nucala

GGlaxo Dba Glaxosmithkline

Phase 3

3 4

Xeljanz

PPrism Pharmaceuticals

Phase 3

1 5

Actemra

CCelltrion

Phase 3

1 6

Tezspire

AstraZeneca

Phase 2

1 7

Gazyva

Roche

Phase 2

1 8

Trimethoprim-Sulfamethoxazole

Astellas

Phase 2

1 9

SHR-1703

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 3

1 10

NS-229

NS Pharma

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Granulomatosis with Polyangiitis1 trial

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Recruiting· NS Pharma logo

NS Pharma·Phase 2·NCT06046222·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NS-229. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NS-229 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NS-229. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NS Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NS Pharma

NS-229

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Granulomatosis with Polyangiitis1 trial

References

Drug Info

Quick Facts

Related News